"Predictivv™ is another step in PRA’s ambitious goal to change the future of clinical development," said CEO Colin Shannon. "As we enter a new era of clinical development led by ideas like adaptive trial design and risk‐based monitoring, we recognized that existing clinical-trial management solutions did not support the real‐time modifications of protocols and operational plans required by adaptive models and the high risks associated with managing this complexity."

The Predictivv™ platform will seamlessly bring together a series of clinical study applications representing the foundation of a true end-to-end clinical development process. Predictivv™ combines data input and continuous feedback from across the spectrum of the trial process, empowering decision support intelligence throughout the entire clinical lifecycle.

"One of the primary goals we established when designing the Predictivv platform was to provide the industry with unprecedented transparency into their portfolio of studies," said Shannon. Through a proprietary analytics engine, Predictivv™ will not only provide transparency into all key processes and their statuses, but it will be capable of proactively identifying process and protocol deviations, enabling course corrections before risks occur.

Among the first applications that will be available in the PredictivvTM platform is Predictivv Connect™. Connect is a highly configurable solution that provides real time insights into every phase of clinical trial management, empowering clients and key stakeholders to connect and use data within their studies in an entirely new way.

With its investment in the Predictivv™ platform, PRA anticipates launching several new applications that focus on key aspects of clinical trial management, including areas such as site selection, patient recruitment and investigator engagement. PredictivvTM applications will be device independent, allowing users to explore data, uncover new insights and take action instantly from any device.